FMS vs GMED

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

GMED exhibits a stable financial profile with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by a Debt/Equity ratio of 0.03. While the current price of $93.70 trades at a significant premium to its Graham Number ($54.65), it remains well below the growth-based intrinsic value of $115.64. The company demonstrates explosive earnings growth (437% YoY) and a consistent track record of beating analyst estimates over 25 quarters. Despite bearish insider sentiment and weak technical trends, the fundamental growth trajectory and liquidity position make it a strong long-term candidate.